Does a selective and potent CXCR3 antagonist SCH 546738 attenuate the development of autoimmune diseases and delays graft rejection?
SCH 546738 is a novel, potent and non-competitive small molecule CXCR3 antagonist. It is efficacious in multiple preclinical disease models. These results demonstrate that therapy with CXCR3 antagonists may serve as a new strategy for treatment of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis, and to prevent transplant rejection.
We found no convincing evidence of syphilis transmission from mothers with persistently negative nontreponemal test results. Only 1 case suggested that transmission may have occurred, and records were incomplete.